Definition of intervention points in prediabetes

The Lancet Diabetes and Endocrinology

Volumn 2, Issue 8, 2014, Pages 667-675

  Ferrannini, Ele ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ANTIDIABETIC AGENT; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE;

BODY WEIGHT DISORDER; CALORIC RESTRICTION; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DYSGLYCEMIA; EDEMA; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; ORAL GLUCOSE TOLERANCE TEST; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; RISK REDUCTION; SCREENING; WEIGHT GAIN; WEIGHT REDUCTION; BIOLOGICAL MODEL; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DISEASE COURSE; HEALTH PROMOTION; LIFESTYLE; MASS SCREENING; MULTIMODALITY CANCER THERAPY; OVERWEIGHT; PREDIABETIC STATE; RISK FACTOR;

CARDIOVASCULAR DISEASES; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; HEALTH PROMOTION; HUMANS; LIFE STYLE; MASS SCREENING; MODELS, BIOLOGICAL; OVERWEIGHT; PREDIABETIC STATE; RISK FACTORS; WEIGHT LOSS;

EID: 84906940729     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(13)70175-X     Document Type: Note

References (96)

1. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004, 27(suppl 1):S5-10. American Diabetes Association.
2. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus 1999, WHO, World Health Organization, Geneva.
3. Kim C, Newton KM, Knopp RH Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care 2002, 25:1862-1868.
4. Mooy JM, Grootenhuis PA, de Vries H, et al. Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study. Diabetologia 1996, 39:298-305.
5. Tabák AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimäki M, Witte DR Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 2009, 373:2215-2221.
6. Borg R, Kuenen JC, Carstensen B, et al. Associations between features of glucose exposure and A1C: the A1C-Derived Average Glucose (ADAG) study. Diabetes 2010, 59:1585-1590. the ADAG Study Group.
7. Bullard KM, Saydah SH, Imperatore G, et al. Secular changes in US Prediabetes prevalence defined by hemoglobin A1c and fasting plasma glucose: National Health and Nutrition Examination Surveys, 1999-2010. Diabetes Care 2013, 36:2286-2293.
8. Barcelo A, Gregg EW, Gerzoff RB, et al. Prevalence of diabetes and intermediate hyperglycemia among adults from the first multinational study of noncommunicable diseases in six Central American countries: the Central America Diabetes Initiative (CAMDI). Diabetes Care 2012, 35:738-740. the CAMDI Collaborative Study Group.
9. Ferrannini E, Massari M, Nannipieri M, Natali A, Ridaura RL, Gonzales-Villalpando C Plasma glucose levels as predictors of diabetes: the Mexico City diabetes study. Diabetologia 2009, 52:818-824.
10. de Vegt F, Dekker JM, Jager A, et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The Hoorn Study. JAMA 2001, 285:2109-2113.
11. Schöttker B, Raum E, Rothenbacher D, Müller H, Brenner H Prognostic value of haemoglobin A1c and fasting plasma glucose for incident diabetes and implications for screening. Eur J Epidemiol 2011, 26:779-787.
12. Ferrannini E, Balkau B, Coppack SW, et al. Insulin resistance, insulin response, and obesity as indicators of metabolic risk. J Clin Endocrinol Metab 2007, 92:2885-2892. the RISC Investigators.
13. Ferrannini E, Natali A, Muscelli E, et al. Natural history and physiological determinants of changes in glucose tolerance in a non-diabetic population: the RISC Study. Diabetologia 2011, 54:1507-1516. the RISC Investigators.
14. Ferrannini E, Nannipieri M, Williams K, Gonzales C, Haffner SM, Stern MP Mode of onset of type 2 diabetes from normal or impaired glucose tolerance. Diabetes 2004, 53:160-165.
15. Mason CC, Hanson RL, Knowler WC Progression to type 2 diabetes characterized by moderate then rapid glucose increases. Diabetes 2007, 56:2054-2061.
16. Ferrannini E, Gastaldelli A, Iozzo P Pathophysiology of prediabetes. Med Clin North Am 2011, 95:327-339. vii-viii.
17. Ferrannini E, Mari A How to measure insulin sensitivity. J Hypertens 1998, 16:895-906.
18. Virtanen KA, Iozzo P, Hällsten K, et al. Increased fat mass compensates for insulin resistance in abdominal obesity and type 2 diabetes: a positron-emitting tomography study. Diabetes 2005, 54:2720-2726.
19. Iozzo P, Turpeinen AK, Takala T, et al. Defective liver disposal of free fatty acids in patients with impaired glucose tolerance. J Clin Endocrinol Metab 2004, 89:3496-3502.
20. Golay A, DeFronzo RA, Ferrannini E, et al. Oxidative and non-oxidative glucose metabolism in non-obese type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1988, 31:585-591.
21. Kelley DE Skeletal muscle fat oxidation: timing and flexibility are everything. J Clin Invest 2005, 115:1699-1702.
22. Ferrannini E, Mari A Beta cell function and its relation to insulin action in humans: a critical appraisal. Diabetologia 2004, 47:943-956.
23. Toschi E, Camastra S, Mari A, et al. A model for assessing insulin secretion and its control under free-living conditions. Diabetes 2001, 50(suppl 1):S178-S179.
24. Mari A, Tura A, Natali A, et al. Impaired beta cell glucose sensitivity rather than inadequate compensation for insulin resistance is the dominant defect in glucose intolerance. Diabetologia 2010, 53:749-756. the RISC Investigators.
25. Abdul-Ghani MA, Tripathy D, DeFronzo RA Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 2006, 29:1130-1139.
26. Ford ES, Zhao G, Li C Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. J Am Coll Cardiol 2010, 55:1310-1317.
27. Kowall B, Rathmann W, Heier M, et al. Categories of glucose tolerance and continuous glycemic measures and mortality. Eur J Epidemiol 2011, 26:637-645.
28. Deedwania P, Patel K, Fonarow GC, et al. Prediabetes is not an independent risk factor for incident heart failure, other cardiovascular events or mortality in older adults: Findings from a population-based cohort study. Int J Cardiol 2013, 168:3616-3622. (Epub ahead of print).
29. Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010, 375:2215-2222. the Emerging Risk Factors Collaboration.
30. Seshasai SR, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011, 364:829-841. the Emerging Risk Factors Collaboration.
31. Sattar N Revisiting the links between glycaemia, diabetes and cardiovascular disease. Diabetologia 2013, 56:686-695.
32. Gale EA Is type 2 diabetes a category error?. Lancet 2013, 381:1956-1957.
33. Morris DH, Khunti K, Achana F, et al. Progression rates from HbA1c 6.0-6.4% and other prediabetes definitions to type 2 diabetes: a meta-analysis. Diabetologia 2013, 56:1489-1493.
34. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405-412.
35. Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial-revisited. Diabetes 2008, 57:995-1001. the DCCT/EDIC Research Group.
36. Ingelsson E, Sullivan LM, Murabito JM, et al. Prevalence and prognostic impact of subclinical cardiovascular disease in individuals with the metabolic syndrome and diabetes. Diabetes 2007, 56:1718-1726.
37. Giorda CB, Avogaro A, Maggini M, et al. Recurrence of cardiovascular events in patients with type 2 diabetes: epidemiology and risk factors. Diabetes Care 2008, 31:2154-2159. the Diabetes and Informatics Study Group.
38. Rijkelijkhuizen JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD, Dekker JM High risk of cardiovascular mortality in individuals with impaired fasting glucose is explained by conversion to diabetes: the Hoorn study. Diabetes Care 2007, 30:332-336.
39. Ford ES Trends in the risk for coronary heart disease among adults with diagnosed diabetes in the U.S.: findings from the National Health and Nutrition Examination Survey, 1999-2008. Diabetes Care 2011, 34:1337-1343.
40. Ford ES Trends in predicted 10-year risk of coronary heart disease and cardiovascular disease among U.S. adults from 1999 to 2010. J Am Coll Cardiol 2013, 61:2249-2252.
41. Pencina MJ, D'Agostino RB, Larson MG, Massaro JM, Vasan RS Predicting the 30-year risk of cardiovascular disease: the Framingham heart study. Circulation 2009, 119:3078-3084.
42. Gerstein HC, Bosch J, Dagenais GR, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012, 367:319-328. the ORIGIN Trial Investigators.
43. Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013, 369:145-154. the Look AHEAD Research Group.
44. Hemmingsen B, Lund SS, Gluud C, et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011, 6. CD008143.
45. Hemmingsen B, Lund SS, Gluud C, et al. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 2011, 343:d6898.
46. Polak JF, Pencina MJ, Pencina KM, O'Donnell CJ, Wolf PA, D'Agostino RB Carotid-wall intima-media thickness and cardiovascular events. N Engl J Med 2011, 365:213-221.
47. Lonn EM, Bosch J, Diaz R, et al. Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN-GRACE). Diabetes Care 2013, 36:2466-2474. the GRACE and ORIGIN Investigators.
48. Ferrannini E The stunned beta cell: a brief history. Cell Metab 2010, 11:349-352.
49. Rossetti L, Giaccari A, DeFronzo RA Glucose toxicity. Diabetes Care 1990, 13:610-630.
50. Yudkin JS, Montori VM, Lipska KJ, Gale EA ADDITION-Europe and the case for diabetes screening. Lancet 2012, 379:313.
51. Collins GS, Mallett S, Omar O, Yu LM Developing risk prediction models for type 2 diabetes: a systematic review of methodology and reporting. BMC Med 2011, 9:103.
52. Griffin SJ, Little PS, Hales CN, Kinmonth AL, Wareham NJ Diabetes risk score: towards earlier detection of type 2 diabetes in general practice. Diabetes Metab Res Rev 2000, 16:164-171.
53. Webb DR, Gray LJ, Khunti K, et al. Screening for diabetes using an oral glucose tolerance test within a western multi-ethnic population identifies modifiable cardiovascular risk: the ADDITION-Leicester study. Diabetologia 2011, 54:2237-2246.
54. Ackermann RT, Finch EA, Brizendine E, Zhou H, Marrero DG Translating the Diabetes Prevention Program into the community. Am J Prev Med 2008, 35:357-363. The DEPLOY Pilot Study.
55. Vanderwood KK, Hall TO, Harwell TS, Butcher MK, Helgerson SD Implementing a state-based cardiovascular disease and diabetes prevention program. Diabetes Care 2010, 33:2543-2545. the Montana Cardiovascular Disease and Diabetes Prevention Program Workgroup.
56. Gillies CL, Lambert PC, Abrams KR, et al. Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. BMJ 2008, 336:1180-1185.
57. Sandbaek A, Griffin SJ, Rutten G, et al. Stepwise screening for diabetes identifies people with high but modifiable coronary heart disease risk. The ADDITION study. Diabetologia 2008, 51:1127-1134.
58. Kozakova M, Palombo C, Eng MP, et al. Fatty liver index, gamma-glutamyltransferase, and early carotid plaques. Hepatology 2012, 55:1406-1415. the RISC Investigators.
59. Bozkurt L, Göbl CS, Tura A, et al. Fatty liver index predicts further metabolic deteriorations in women with previous gestational diabetes. PLoS One 2012, 7:e32710.
60. Wang-Sattler R, Yu Z, Herder C, et al. Novel biomarkers for pre-diabetes identified by metabolomics. Mol Syst Biol 2012, 8:615.
61. Ferrannini E, Natali A, Camastra S, et al. Early metabolic markers of the development of dysglycemia and type 2 diabetes and their physiological significance. Diabetes 2013, 62:1730-1737.
62. Gaede P, Lund-Andersen H, Parving HH, Pedersen O Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358:580-591.
63. Gaede P, Valentine WJ, Palmer AJ, et al. Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study. Diabetes Care 2008, 31:1510-1515.
64. Kowall B, Rathmann W, Heier M, et al. Impact of weight and weight change on normalization of prediabetes and on persistence of normal glucose tolerance in an older population: the KORA S4/F4 study. Int J Obes (Lond) 2012, 36:826-833.
65. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997, 20:537-544.
66. Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344:1343-1350. the Finnish Diabetes Prevention Study Group.
67. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403. the Diabetes Prevention Program Research Group.
68. Kosaka K, Noda M, Kuzuya T Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Res Clin Pract 2005, 67:152-162.
69. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006, 49:289-297. the Indian Diabetes Prevention Programme (IDPP).
70. Lindström J, Ilanne-Parikka P, Peltonen M, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006, 368:1673-1679. the Finnish Diabetes Prevention Study Group.
71. Li G, Zhang P, Wang J, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 2008, 371:1783-1789.
72. Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet 2012, 379:2243-2251. the Diabetes Prevention Program Research Group.
73. Wing RR Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med 2010, 170:1566-1575. the Look AHEAD Research Group.
74. Gregg EW, Chen H, Wagenknecht LE, et al. Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA 2012, 308:2489-2496. the Look AHEAD Research Group.
75. Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005, 353:2111-2120.
76. Redman LM, Heilbronn LK, Martin CK, et al. Metabolic and behavioral compensations in response to caloric restriction: implications for the maintenance of weight loss. PLoS One 2009, 4:e4377. the Pennington CALERIE Team.
77. Eckel RH, Kahn SE, Ferrannini E, et al. Obesity and type 2 diabetes: what can be unified and what needs to be individualized?. J Clin Endocrinol Metab 2011, 96:1654-1663.
78. Hall KD, Sacks G, Chandramohan D, et al. Quantification of the effect of energy imbalance on bodyweight. Lancet 2011, 378:826-837.
79. Després JP, Poirier P Diabetes: looking back at Look AHEAD-giving lifestyle a chance. Nat Rev Cardiol 2013, 10:184-186.
80. Griffin SJ, Borch-Johnsen K, Davies MJ, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 2011, 378:156-167.
81. Eddy DM, Schlessinger L, Kahn R Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med 2005, 143:251-264.
82. Gong Q, Gregg EW, Wang J, et al. Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia 2011, 54:300-307.
83. Saaristo T, Moilanen L, Korpi-Hyövälti E, et al. Lifestyle intervention for prevention of type 2 diabetes in primary health care: one-year follow-up of the Finnish National Diabetes Prevention Program (FIN-D2D). Diabetes Care 2010, 33:2146-2151.
84. Knowler WC, Fowler SE, Hamman RF, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009, 374:1677-1686. the Diabetes Prevention Program Research Group.
85. The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. Diabetes Care 2012, 35:723-730. Diabetes Prevention Program Research Group.
86. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002, 359:2072-2077. the STOP-NIDDM Trail Research Group.
87. Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006, 368:1096-1105. the DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators.
88. DeFronzo RA, Tripathy D, Schwenke DC, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011, 364:1104-1115. the ACT NOW Study.
89. Defronzo RA, Tripathy D, Schwenke DC, et al. Prevention of Diabetes With Pioglitazone in ACT NOW: Physiologic Correlates. Diabetes 2013, 62:3920-3926. the ACT NOW Study.
90. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003, 290:486-494. the STOP-NIDDM Trial Research Group.
91. Holman RR, Haffner SM, McMurray JJ, et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010, 362:1463-1476. the NAVIGATOR Study Group.
92. Kahn R Reducing the impact of diabetes: is prevention feasible today, or should we aim for better treatment?. Health Aff (Millwood) 2012, 31:76-83.
93. Rosenstock J Reflecting on type 2 diabetes prevention: more questions than answers!. Diabetes Obes Metab 2007, 9(suppl 1):3-11.
94. Nathan DM, Davidson MB, DeFronzo RA, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007, 30:753-759. the American Diabetes Association.
95. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012, 55:1577-1596.
96. Neiberg RH, Wing RR, Bray GA, et al. Patterns of weight change associated with long-term weight change and cardiovascular disease risk factors in the Look AHEAD Study. Obesity (Silver Spring) 2012, 20:2048-2056. the Look AHEAD Research Group.